



Deposited via The University of Sheffield.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/110871/>

Version: Accepted Version

---

**Article:**

Stevens, K.N., Vachon, C.M., Lee, A.M. et al. (2011) Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer. *Cancer Research*, 71 (19). pp. 6240-6249. ISSN: 0008-5472

<https://doi.org/10.1158/0008-5472.CAN-11-1266>

---

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.

Published in final edited form as:

*Cancer Res.* 2011 October 1; 71(19): 6240–6249. doi:10.1158/0008-5472.CAN-11-1266.

## Common breast cancer susceptibility loci are associated with triple negative breast cancer

Kristen N. Stevens<sup>1</sup>, Celine M. Vachon<sup>\*1</sup>, Adam M. Lee<sup>2</sup>, Susan Slager<sup>1</sup>, Timothy Lesnick<sup>1</sup>, Curtis Olswold<sup>1</sup>, Peter A. Fasching<sup>3</sup>, Penelope Miron<sup>4</sup>, Diana Eccles<sup>5</sup>, Jane E. Carpenter<sup>6</sup>, Andrew K. Godwin<sup>7</sup>, Christine Ambrosone<sup>8</sup>, Robert Winqvist<sup>9</sup>, Hiltrud Brauch on behalf of the GENICA consortium<sup>10,11</sup>, Marjanka K. Schmidt<sup>12</sup>, Angela Cox<sup>13</sup>, Simon S. Cross<sup>14</sup>, Elinor Sawyer<sup>15</sup>, Arndt Hartmann<sup>16</sup>, Matthias W. Beckmann<sup>17</sup>, Rüdiger Schulz-Wendtland<sup>18</sup>, Arif B. Ekici<sup>19</sup>, William J Tapper<sup>5</sup>, Susan M Gerty<sup>5</sup>, Lorraine Durcan<sup>5</sup>, Nikki Graham<sup>5</sup>, Rebecca Hein<sup>20</sup>, Stephan Nickels<sup>20</sup>, Dieter Flesch-Janys<sup>21</sup>, Judith Heinz<sup>21</sup>, Hans-Peter Sinn<sup>22</sup>, Irene Konstantopoulou<sup>23</sup>, Florentia Fostira<sup>23</sup>, Dimitrios Pectasides<sup>24</sup>, Athanasios M. Dimopoulos<sup>25</sup>, George Fountzilas<sup>26</sup>, Christine L. Clarke<sup>6</sup>, Rosemary Balleine<sup>27</sup>, Janet E. Olson<sup>1</sup>, Zachary Fredericksen<sup>1</sup>, Robert B. Diasio<sup>2</sup>, Harsh Pathak<sup>28</sup>, Eric Ross<sup>29</sup>, JoEllen Weaver<sup>28</sup>, Thomas Rüdiger<sup>30</sup>, Asta Försti<sup>31</sup>, Thomas Dünnebie<sup>32</sup>, Foluso Ademuyiwa<sup>33</sup>, Swati Kulkarni<sup>34</sup>, Katri Pylkäs<sup>9</sup>, Arja Jukkola-Vuorinen<sup>35</sup>, Yon-Dschun Ko<sup>36</sup>, Erik Van Limbergen<sup>37</sup>, Hilde Janssen<sup>37</sup>, Julian Peto<sup>38</sup>, Olivia Fletcher<sup>39</sup>, Graham G. Giles<sup>40</sup>, Laura Baglietto<sup>40</sup>, Senno Verhoef<sup>41</sup>, Ian Tomlinson<sup>42</sup>, Veli-Matti Kosma<sup>43</sup>, Jonathan Beesley<sup>44</sup>, Dario Greco<sup>45</sup>, Carl Blomqvist<sup>46</sup>, Astrid Irwanto<sup>47</sup>, Jianjun Liu<sup>47</sup>, Fiona M. Blows<sup>48</sup>, Sarah-Jane Dawson<sup>48</sup>, Sara Margolin<sup>49</sup>, Arto Mannermaa<sup>43</sup>, Nicholas G. Martin<sup>50</sup>, Grant W Montgomery<sup>50</sup>, Diether Lambrechts<sup>51,52</sup>, Isabel dos Santos Silva<sup>38</sup>, Gianluca Severi<sup>40</sup>, Ute Hamann<sup>31</sup>, Paul Pharoah<sup>48</sup>, Douglas F. Easton<sup>53</sup>, Jenny Chang-Claude<sup>19</sup>, Drakoulis Yannoukakos<sup>22</sup>, Heli Nevanlinna<sup>45</sup>, Xianshu Wang<sup>54</sup>, and Fergus J. Couch<sup>54</sup>

<sup>1</sup> Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA <sup>2</sup> Department of Pharmacology, Mayo Clinic, Rochester, MN, USA <sup>3</sup> University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of hematology and Oncology, Los Angeles, CA, USA <sup>4</sup> Dana Farber Cancer Institute, Boston, MA, USA <sup>5</sup> University of Southampton, Faculty of Medicine, Southampton University Hospitals NHS Trust, Southampton UK. <sup>6</sup> Australian Breast Cancer Tissue Bank, University of Sydney at the Westmead Millennium Institute, Westmead, NSW, Australia <sup>7</sup> Department of Pathology and Laboratory Medicine, Kansas University Medical Center, Lawrence, KS, USA <sup>8</sup> Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA <sup>9</sup> Laboratory of Cancer Genetics, Department of Clinical Genetics and Biocenter Oulu, University of Oulu, Oulu University Hospital, Oulu, Finland <sup>10</sup> Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, and University Tübingen, Germany <sup>11</sup> Gene Environment Interaction and Breast Cancer in Germany (GENICA): Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, and University Tübingen, Germany (HB, Christina Justenhoven); Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany (Ute Hamann); Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany (YDK, Christian Baisch); Institute of Pathology, Medical Faculty of the University of Bonn, Germany (Hans-Peter Fischer); Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, Germany (Thomas Bruening, Beate Pesch, Volker Harth, Sylvia Rabstein) <sup>12</sup> Division of Experimental Therapy and Molecular Pathology and Division of Epidemiology (MKS), Netherlands Cancer Institute – Antoni van

\*Correspondence: Celine M. Vachon, Department of Health Sciences Research, Mayo Clinic, Charlton 6-239, 200 First St. SW, Rochester, MN 55905, USA; Tel: 507-284-9901; Fax: 507-266-2478; vachon.celine@mayo.edu.

Leeuwenhoek Hospital, Amsterdam, The Netherlands<sup>13</sup> Institute for Cancer Studies, Department of Oncology, Faculty of Medicine, Dentistry & Health, University of Sheffield, UK<sup>14</sup> Academic Unit of Pathology, Department of Neuroscience, Faculty of Medicine, Dentistry & Health, University of Sheffield, UK<sup>15</sup> National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre, Guy's & St. Thomas' NHS Foundation Trust, London, UK<sup>16</sup> Friedrich-Alexander University Erlangen-Nuremberg, Institute of Pathology, University Hospital Erlangen, Erlangen, Germany.<sup>17</sup> Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, University Breast Center Franconia, Department of Gynecology and Obstetrics, Erlangen, Germany.<sup>18</sup> Friedrich-Alexander University Erlangen-Nuremberg, Institute of Diagnostic Radiology, University Hospital Erlangen, Erlangen, Germany.<sup>19</sup> Friedrich-Alexander University Erlangen-Nuremberg, Institute of Human Genetics, Erlangen, Germany.<sup>20</sup> Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany<sup>21</sup> Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg, Germany<sup>22</sup> Department of Pathology, University Hospital Heidelberg, Heidelberg, Germany<sup>23</sup> Molecular Diagnostics Laboratory IRRP, National Centre for Scientific Research "Demokritos", Athens, Greece<sup>24</sup> Department of Internal Medicine, Oncology Section, "Hippokration" Hospital; Athens, Greece<sup>25</sup> Department of Clinical Therapeutics, "Alexandra" Hospital, University of Athens School of Medicine, Athens, Greece<sup>26</sup> Department of Medical Oncology, Aristotle University of Thessaloniki, Papageorgiou Hospital, Thessaloniki, Greece<sup>27</sup> Dept of Translational Oncology, Westmead Hospital, Western Sydney Local Health Network, Westmead, NSW, Australia<sup>28</sup> Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA<sup>29</sup> Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, PA, USA<sup>30</sup> Institute of Pathology, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany<sup>31</sup> Division of Molecular Genetic Epidemiology, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany and Center for Primary Health Care Research, University of Lund, Malmö, Sweden<sup>32</sup> Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany<sup>33</sup> Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA<sup>34</sup> Dept of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA<sup>35</sup> Department of Oncology, Oulu University Hospital, University of Oulu, Oulu, Finland<sup>36</sup> Department of Internal Medicine, Evangelische Kliniken Johanniter- und Waldkrankenhaus Bonn gGmbH, Bonn, Germany<sup>37</sup> Multidisciplinary Breast Center, University Hospital Gasthuisberg, Leuven, Belgium<sup>38</sup> Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK<sup>39</sup> Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK<sup>40</sup> Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia & Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Australia<sup>41</sup> Family Cancer Clinic (SV), Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands<sup>42</sup> Wellcome Trust Centre for Human Genetics and Oxford Comprehensive Biomedical Research Centre, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK<sup>43</sup> Institute of Clinical Medicine, Department of Pathology, University of Eastern Finland and Kuopio University Hospital; Biocenter Kuopio, Kuopio, Finland<sup>44</sup> Genetics and Population Health Division, Queensland Institute of Medical Research, Brisbane, Australia<sup>45</sup> Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland<sup>46</sup> Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland<sup>47</sup> Human Genetics Division, Genome Institute of Singapore, Singapore.<sup>48</sup> Department of Oncology and Department of Public Health and Primary Care University of Cambridge, Cambridge, UK<sup>49</sup> Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden<sup>50</sup> QIMR GWAS Collective, Queensland Institute of Medical Research, Brisbane, Australia<sup>51</sup> Vesalius Research Center, VIB, Leuven, Belgium<sup>52</sup> Vesalius Research Center, University of Leuven, Leuven, Belgium<sup>53</sup> Department of Genetic Epidemiology, Cancer Research UK Genetic Epidemiology Unit, Strangeways Research Laboratory, Cambridge, UK<sup>54</sup> Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

## Abstract

Triple negative breast cancers are an aggressive subtype of breast cancer with poor survival, but there remains little known about the etiological factors which promote its initiation and development. Commonly inherited breast cancer risk factors identified through genome wide association studies (GWAS) display heterogeneity of effect among breast cancer subtypes as defined by estrogen receptor (ER) and progesterone receptor (PR) status. In the Triple Negative Breast Cancer Consortium (TNBCC), 22 common breast cancer susceptibility variants were investigated in 2,980 Caucasian women with triple negative breast cancer and 4,978 healthy controls. We identified six single nucleotide polymorphisms (SNPs) significantly associated with risk of triple negative breast cancer, including rs2046210 (ESR1), rs12662670 (ESR1), rs3803662 (TOX3), rs999737 (RAD51L1), rs8170 (19p13.11) and rs8100241 (19p13.11). Together, our results provide convincing evidence of genetic susceptibility for triple negative breast cancer.

## Keywords

genetic susceptibility; neoplasms; association study; subtypes; common variant

## Introduction

Triple negative (TN) breast cancers are a biologically and clinically distinct subtype of breast cancer, defined as tumors that exhibit low or no expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) (1). Women with TN disease account for approximately 15% of all invasive breast cancers and are more likely to be younger, African American, have an earlier age at menarche, higher body mass index during premenopausal years, higher parity, and a lower lifetime duration of breast feeding (2-4). In addition, TN tumors are typically of higher histologic grade and are associated with more aggressive disease and poorer survival (1, 5, 6). These differences in tumor pathology, non-genetic risk factors, and survival among women with TN disease suggest that the etiology of these tumors may differ from other breast cancer subtypes.

Genome wide association studies (GWAS) have recently identified common, low-penetrance susceptibility variants that are associated with risk of breast cancer (7-16). Growing evidence suggests substantial heterogeneity by tumor subtype, defined by hormone receptor status, for associations with these SNPs. In particular, variants in 5p12, *FGFR2*, 8q24, 1p11.2, 9p21.3, 10q21.2, and 11q13 are associated with risk of developing ER-positive tumors (9-12, 14, 17, 18) but not ER-negative tumors, whereas variants in 2q35, *TOX3*, *LSP1*, *MAP3K1*, *TGFB1* and *RAD51L1* are associated with both ER-positive and ER-negative disease (19). To date, no variants have been specifically associated with ER-negative or TN disease. However, variants at *TOX3*, 2q35, and two distinct signals at 19p13.1 have been associated with breast cancer risk in *BRCA1* mutation carriers, who predominantly develop tumors displaying an ER-negative and TN phenotype (15, 20, 21). Thus, additional studies specifically investigating ER-negative and TN disease are necessary to understand genetic susceptibility to these breast cancer subtypes.

Here we report on the first TNBCC study of genetic susceptibility to TN breast cancer in which associations between 22 common breast cancer susceptibility loci and risk among 2,980 cases and 4,978 controls were evaluated. This comprehensive study included 21 common variants from all known susceptibility loci identified through currently published breast cancer GWAS (1p11.2, 2q35, 3p24/*NEK10*, 5p12/*MRPS30*, *MAP3K1*, *ESR1*, 8q24, 9p21.3, 9q31.2, 10p15.1, 10q21.2/*ZNF365*, 10q22.3/*ZMIZ1*, *FGFR2*, *LSP1*, 11q13, *RAD51L1*, *TOX3*, 17q23/*COX11*, 19p13.1) and a SNP from *CASP8* identified in a

candidate-gene study of *CASP8* (22, 23). We show that SNPs from four of these loci are strongly associated with risk of TN breast cancer.

## Materials and Methods

### Ethics Statement

Study subjects were recruited on protocols approved by the Institutional Review Boards at each participating institution, and all subjects provided written informed consent.

### Study populations

Samples from several TN breast cancer case-control series, including 2,778 TN breast cancer cases and 1,406 unaffected controls, were genotyped on the iPLEX platform. These subjects were ascertained by 22 studies in 10 different countries: United States, Australia, Great Britain, Finland, Germany, Netherlands, Greece, Ireland, and Sweden. These included cases from the KBCP and POSH cohort studies, cases and controls from the MCCC cohort study, and cases and controls from established population-based breast cancer case-control studies (BBCS, GENICA, MARIE, SEARCH), hospital or clinic based case-control studies (ABCS, BIGGS, LMBC, MCBCS, OBSC, SBCS, and RPCI), case-only studies with geographically matched controls (BBCC, KARBAC, SKKDKFZS, FCCC), and unselected cases identified in tumor collections (DFCI, ABCTB, DEMOKRITOS). Data from an ongoing GWAS of TN breast cancer, including cases and controls from several of the studies described above, and the TN cases from the HEBCS GWAS along with population control data (n=273) were also included (24). In addition, data from four publicly available control GWAS data sets (Wellcome Trust Case Control Consortium UK 1958 Birth Cohort (WTCCC), National Cancer Institute's Cancer Genetic Markers of Susceptibility (CGEMS) project, Cooperative Health Research in the Region of Augsburg (KORA) study, and the Australian Twin Cohort study from the Queensland Institute of Medical Research (QIMR)) (n=3,593) were utilized. Age distributions and years of diagnosis for individual study sites are provided in **Supplementary Table 1**, and these studies are described in more detail in Supplementary Material.

### Pathology and tumor markers

A TN breast cancer case was defined as an individual with an ER-negative, PR-negative and HER2-negative (0 or 1 by immunohistochemical staining (IHC)) breast cancer diagnosed after age 18. Criteria used for defining ER, PR, and HER2 status varied by study. These are described in detail in **Supplementary Table 2**. CK5/6 and EGFR IHC data for identification of basal tumors were not available.

### Genotyping

The following 22 SNPs were genotyped on the iPLEX platform: rs11249433 (1p11.2), rs13387042 (2q35), rs4973768 (3p24), rs10941679 (5p12), rs889312 (*MAP3K1*), rs2046210 (*ESR1*), rs12662670 (*ESR1*, surrogate for rs9397435), rs13281615 (8q24), rs1011970 (9p21.3), rs865686 (9q31.2), rs2380205 (10p15.1), rs10509168 (10q21.2, surrogate for rs10995190), rs704010 (10q21.2), rs2981582 (*FGFR2*), rs3817198 (*LSP1*), rs614367 (11q13), rs999737 (*RAD51LI*), rs3803662 (*TOX3*), rs6504950 (17q23), rs8170 (19p13.11), rs8100241 (19p13.11), and rs17468277 (tagSNP for *CASP8* D302H). For 10q21.2, rs10509168 was genotyped as a surrogate for rs10995190 (14).

Genotype data for 22 SNPs were generated for 2,778 cases and 1,406 controls using a single multiplex on the iPLEX Mass Array platform (Sequenom). Samples were plated by study as random mixtures of cases and controls with no-template and CEPH controls in every plate. Genotyping quality for SNPs and samples was evaluated using an iterative quality control

(QC) process. SNPs and samples were excluded based on the following criteria: SNP call rate <95%, Hardy-Weinberg equilibrium (HWE) p-value <0.01 among controls, and sample call rate <95%. The final dataset of 2707 cases and 1385 controls exhibited SNP call rates >99%, HWE p-value >0.01, and sample call rates >95%.

In addition, genotype data from cases and controls included in a TN GWAS were available to supplement the iPLEX genotypes. Cases from 10 study sites (ABCTB, BBCC, DFCl, FCCC, GENICA, MARIE, MCBSCS, MCCS, POSH, SBCS) were genotyped using the Illumina 660-Quad SNP array. A subset of MARIE cases were genotyped using the Illumina CNV370 SNP array. HEBCS cases and controls were genotyped using the Illumina 550-Duo SNP array. GWAS data for public controls were generated using the following arrays: Illumina 660-Quad (QIMR), Illumina 550(v1) (CGEMS), Illumina 550 (KORA), and Illumina 1.2M (WTCCC). For HEBCS, population allele and genotype frequencies on 221 healthy population controls genotyped on Illumina HumanHap 370CNV in the NordicDB, a Nordic pool and portal for genome-wide control data, were obtained from the Finnish Genome Center (25). These GWAS data were independently evaluated by an iterative QC process with the following exclusion criteria: minor allele frequency (MAF) <0.01, call rate <95%, HWE p-value <1×10<sup>-7</sup> among controls and sample call rate <98%. When DNA was available (n=1,402), we re-genotyped samples from the TN GWAS as part of the iPLEX study in an effort to obtain as much data as possible from a single platform. Therefore, following preferential selection of data from the iPLEX study, genotypes for an additional 273 cases and 3,593 controls were included from the GWAS data (**Table 1**). No GWAS genotype data were available for rs10941679 (5p12), rs2046210 (*ESR1*), rs6504950 (17q23) and only partial data were available for five other SNPs because of the absence of these SNPs from some or all of the GWAS genotyping platforms (**Table 1**). As a further measure of genotype quality, genotype concordance was evaluated for the 1,402 samples included in both the iPLEX and GWAS. Eighteen of 19 SNPs, had concordance rates >98% and rs8100241 showed concordance of 96.3% .

## Statistical methods

Allele frequencies for each of the 22 SNPs included in these analyses were estimated using the iPLEX genotype data and the combined GWAS and iPLEX data for cases, controls, and all subjects (**Supplementary Table 3**). Associations for TN breast cancer were estimated using unconditional logistic regression adjusted for country of residence. The sites were categorized by country of origin (American, Australian, British, Finnish, German, Greek, Irish, and Swedish) (**Table 1**). SNPs were coded for a gene-dose effect by assigning a three-level (0, 1, 2) variable to each genotype (log-additive model). We calculated p-values, odds ratios (ORs) and 95% confidence intervals from these logistic regressions. Pair-wise interactions were tested by including multiplicative interaction terms in logistic regression models. Homogeneity of ORs by country was tested using the Q statistic (26) and the extent of heterogeneity was estimated by the I<sup>2</sup> statistic (27). All analyses were conducted using SAS version 9.2, R version 2.11.0, or Plink version 1.07.

## Results

We evaluated 22 breast cancer susceptibility SNPs identified in breast cancer GWAS for associations with TN disease using genotype data from an iPLEX study of the 22 SNPs supplemented with data from a TN GWAS. The combined data resulted in a case-control study of 2,980 cases and 4,978 controls from 25 studies in eight countries (**Table 1**). All 22 SNPs were in Hardy-Weinberg equilibrium among controls at p>0.01. Only rs17468277 and rs1011970 showed evidence of heterogeneity by country (rs17468277: p=0.047, I<sup>2</sup>=50.8%; rs1011970: p=0.093, I<sup>2</sup>=42.8%). Of the 22 SNPs from 20 loci, eight were significantly associated with risk of TN breast cancer (p<0.05) (**Table 2**). Six SNPs from four loci,

rs2046210 ( $p=4.38 \times 10^{-7}$ ), rs12662670 ( $p=1.13 \times 10^{-4}$ ), rs999737 ( $p=2.96 \times 10^{-4}$ ), rs3803662 ( $p=3.66 \times 10^{-5}$ ), rs8170 ( $p=2.25 \times 10^{-8}$ ), and rs8100241 ( $p=8.66 \times 10^{-7}$ ), remained significant after correction for multiple testing ( $p < 2.27 \times 10^{-3}$ ). Adjustment for age did not change the magnitude or significance of our results. In addition, we did not find evidence of significant interactions with age for any of the 22 SNPs.

Rs2046210, located upstream of *ESR1* on chromosome 6q25.1, exhibited a strong association with TN disease [odds ratio (OR)=1.29, 95% Confidence Interval (CI) 1.17 – 1.42;  $p=4.38 \times 10^{-7}$ ] (**Figure 1a**), whereas rs12662670, located further upstream of *ESR1*, displayed a similar effect but slightly less significant association with TN disease [OR=1.33-fold, 95% CI 1.15 – 1.53;  $p=1.13 \times 10^{-4}$ ] (**Figure 1b**). To assess the independence of these two *ESR1* SNPs, which are not correlated in HapMap subjects of European ancestry ( $r^2=0.09$ ), we included both SNPs in a multivariate model. Rs2046210 was more strongly associated with TN risk than rs12662670 [rs2046210 OR=1.24, 95% CI 1.12 – 1.38;  $p=5.64 \times 10^{-5}$ ; rs12662670 OR=1.20, 95% CI 1.00 – 1.44;  $p=0.053$ ] in this model, suggesting that rs2046210 may account in part for these two associations. In addition, two SNPs at 19p13.1 shown to have genome wide significant associations with breast cancer in *BRCA1* mutation carriers, were highly significantly associated with TN breast cancer [rs8170: OR=1.27, 95% CI 1.17 – 1.38;  $p=2.25 \times 10^{-8}$ ] [rs8100241: OR=0.84, 95% CI 0.78 – 0.90;  $p=8.66 \times 10^{-7}$ ] (**Figure 1c,d**). Multivariate modeling of these two SNPs, which are moderately correlated in HapMap subjects of European ancestry ( $r^2=0.74$ ), showed that rs8170 is more strongly associated with TN breast cancer risk [rs8170: OR=1.22, 95% CI 1.10 – 1.34;  $p=7.56 \times 10^{-5}$ ; rs8100241: OR=0.90, 95% CI 0.83 – 0.98;  $p=0.014$ ] although both variants are retained in the model. Additionally, rs3803662 (*TOX3*), which has been strongly associated with risk of ER-negative breast cancer (OR=1.15,  $p=2.1 \times 10^{-10}$ ) (19), was associated with a 1.17-fold increase in risk of TN disease [OR=1.17, 95% CI 1.09 – 1.26;  $p=3.66 \times 10^{-5}$ ] (**Figure 1e**). Likewise, the rs999737 (*RAD51LI*) SNP was significantly associated with risk of TN breast cancer [rs999737 OR=0.86, 95% CI 0.80 – 0.93;  $p=2.96 \times 10^{-4}$ ] (**Figure 1f**). In contrast, rs17468277 (*ALS2CRI2/CASP8*) ( $p=0.005$ ) was not significantly associated with TN breast cancer risk after correction for multiple testing, suggesting that this result should be interpreted with caution. None of these six SNPs showed evidence of heterogeneity by country (**Figure 1**). To further understand the influence of variants in the 6q25.1 and 19p13.11 loci on TN risk, we looked for statistical interactions between the SNPs in these regions. While there was no evidence for a statistical interaction between rs2046210 and rs1266270 ( $p=0.820$ ) at 6q25.1, we found strong evidence of an interaction ( $p=0.004$ ) between rs8170 and rs8100241 from 19p13.1, in a multiplicative model.

Next we performed a subset analysis using the iPLEX data alone (2,707 cases, 1,385 controls) for the 19 SNPs with both iPLEX and GWAS genotypes to assess the consistency of our results. Analysis of associations with TN disease in the iPLEX-only dataset showed that odds ratios for the 19 SNPs were consistent in both direction and magnitude of effect compared to the analysis using all available genotype data, although some variation in the significance of the associations was observed (**Table 2**). Four of the SNPs significantly associated with TN breast cancer in the overall analysis retained statistical significance in the iPLEX-only analysis (rs12662670  $p=3.52 \times 10^{-4}$ ; rs3803662  $p=8.25 \times 10^{-4}$ ; rs8170  $p=7.30 \times 10^{-8}$ ; rs8100241  $p=1.81 \times 10^{-6}$ ) after correction for multiple testing. Results were unchanged for rs2046210 from the *ESR1* locus, because the overall analysis was restricted to iPLEX data as a result of missing GWAS data for this variant. Finally, while the rs999737 (*RAD51LI*) SNP was only marginally associated with TN breast cancer risk in the iPLEX-only analysis (rs999737  $p=0.053$ ), the estimate of effect for this SNP was consistent with the effect observed in the overall analysis.

Importantly, genotype data from a subset of these cases and controls have previously been used in association studies involving a number of these SNPs by the Breast Cancer Association Consortium (BCAC). To avoid duplication and to assess the degree to which these BCAC samples influenced our results, we also performed a subset analysis in which we excluded all cases and controls used in the BCAC studies (n=1,819 cases; n=4,038 controls) (**Supplementary Table 4**). The effect estimates and significance of associations with TN disease in either the iPLEX or combined analyses were not substantially modified following the removal of these cases and controls (**Supplementary Table 5**).

## Discussion

Here we report on the first study by the TNBCC and the largest study to date of genetic susceptibility to TN breast cancer, which is comprised 2,980 cases and 4,978 controls from 25 studies in eight countries. We show that a subset of breast cancer susceptibility SNPs identified through GWAS are also associated with risk of TN breast cancer. Specifically, we determined that six breast cancer susceptibility SNPs from four loci- rs2046210 (*ESR1*), rs12662670 (*ESR1*), rs999737 (*RAD51L1*), rs3803662 (*TOX3*), rs8170 (19p13.1) and rs8100241 (19p13.1)- are associated with risk of TN breast cancer. Of these, rs8170 (19p13.1) achieved genome-wide significance ( $p=2.25 \times 10^{-8}$ ). Overall, these findings provide strong evidence of genetic susceptibility to triple negative breast cancer.

We identified highly significant associations between SNPs at 6q25.1 and risk of TN breast cancer, including rs12662670 ( $p=1.13 \times 10^{-4}$ ) and rs2046210, which reached near genome-wide significance ( $p=4.38 \times 10^{-7}$ ). These variants are located approximately 30kb and 60kb upstream of the first untranslated exon and 180kb and 210kb upstream of the first coding exon of *ESR1*, which encodes the estrogen receptor- $\alpha$  protein.

The rs2046210 SNP was originally reported in a breast cancer GWAS in Chinese women (13) where a stronger association among ER-negative than ER-positive breast cancers was observed. Importantly, the magnitude of effect in this TN study [OR=1.29, 95% CI 1.17 – 1.42] was identical to that reported for ER-negative breast cancer in the Chinese study [OR=1.29, 95% CI 1.21-1.37]. In contrast, a study of women of European ancestry did not observe an association with breast cancer, although analyses were not stratified by ER status (28). When combined with our results the suggestion is that this SNP may be specifically associated with TN or ER-negative disease. The second variant in the *ESR1* locus, rs12662670, was originally associated with breast cancer in the same study of women of European ancestry [OR=1.12, 95% CI 1.03 – 1.21] and was used as a surrogate for rs9397435, which is associated with breast cancer risk [OR=1.15, 95% CI 1.06 – 1.25] independently of rs2046210 (28). Here rs12662670 showed a strong influence on TN breast cancer risk [OR=1.33, 95% CI 1.15 – 1.53] again suggesting that variation in the *ESR1* loci is specifically associated with risk of ER-negative and/or TN breast cancer. It remains to be determined whether a single locus represented by rs2046210 or two loci accounted for by rs2046210 and rs9397435, are associated with ER-negative and TN breast cancer at chromosome 6q25.

Since TN breast cancer is defined in part by the absence of expression of estrogen receptors, we can speculate that inherited variation may down-regulate *ESR1* expression and promote formation of ER $\alpha$  negative tumors. However, recent studies in mice have shown that the mammary stem cell compartment can be regulated by 17 $\beta$ -estradiol and progesterone through a paracrine-signalling mechanism from steroid receptor-positive luminal cells to steroid receptor-negative stem cells (29, 30). Thus, SNPs in the *ESR1* locus may promote expansion of receptor negative precursors and subsequent development of TN tumors. Interestingly, variation in the 5' region of *ESR1* has been associated with an increased risk

of breast cancer relapse in a British prospective cohort study (31), which was accounted for by including tumor grade and nodal status in multivariate models. Thus the causal SNPs in this area may be associated with a more aggressive tumor phenotype.

The SNPs rs8170 ( $p=2.25 \times 10^{-8}$ ) and rs8100241 ( $p=8.66 \times 10^{-7}$ ) located at 19p13.1 were first identified as modifiers of breast cancer risk in *BRCA1* carriers (15) and as risk factors for ovarian cancer (32) and were also shown to be significantly associated with ER-negative breast cancer (15). In this study we showed that rs8170 displayed a genome wide significant association with TN breast cancer, suggesting that we can now identify variation in the 19p13.1 locus as a risk factor for TN disease. Interestingly, rs8170 attenuated the significance of rs8100241 when the SNPs were included in a multivariate regression model for breast cancer, whereas these both SNPs retained significance in multivariate models evaluating effects on *BRCA1* associated breast cancer and ER-negative breast cancer (15). In addition, our data suggest that these SNPs have a multiplicative effect on TN breast cancer risk. Further studies are required to determine whether these SNPs represent independent signals in the 19p13.1 locus. Additional studies are also needed to identify the underlying causative genetic events in this locus and to determine if the causative events for *BRCA1*, ER-negative, and TN breast cancer as well as ovarian cancer are in common.

These 19p13.1 variants are located in a cluster of genes including *C19orf62*, *ANKLE1*, and *ABHD8*. *ABHD8* encodes the abhydrolase domain containing 8 protein, which is a gene of uncharacterized function, and is located about 13 kb downstream of both rs8170 and rs8100241. The SNP rs8170 is located within *C19orf62*, which encodes the MERIT40 protein, while rs8100241 is located within *ANKLE1*, a protein of unknown function which encodes ankyrin repeat and LEM domains. MERIT40 is the most plausible candidate in this region for breast cancer susceptibility because it is a component of the *BRCA1*-A complex and is required to ensure the integrity and localization of this complex during the repair of DNA double-strand breaks, specifically through the recruitment and retention of the *BRCA1*-*BARD1* ubiquitin ligase and the *BRCC36* deubiquitination enzyme (33-35). However, it remains to be determined whether the causal variants at 19p13.1 alter MERIT40 expression or function or influence other genes in the region such as *ANKLE1* or *ABHD8*.

We also found that variants in *RAD51L1* (rs999737,  $p=2.96 \times 10^{-4}$ ) and *TOX3* (rs3803662,  $p=3.66 \times 10^{-5}$ ) were strongly associated with risk of TN breast cancer. Rs999737 (*RAD51L1*) was originally identified in a recent breast cancer GWAS of women of European ancestry (12). Detailed studies of breast tumors have suggested that rs999737 is associated with both ER-positive and ER-negative breast cancer, which is consistent with our findings. *RAD51L1* is a member of the Rad51-like family and functions in the double-strand break repair and homologous recombination pathway (36). When coupled with the association of the 19p13.1/MERIT40 locus with TN, the suggestion is that modification of DNA repair genes is an important mechanism involved in predisposition to TN breast cancer. The SNP rs3803662, located telomeric to the gene *TOX3*, was also strongly associated with TN breast cancer in our study ( $p=3.66 \times 10^{-5}$ ). This SNP was originally identified in two GWAS of breast cancer (7, 9) and has been associated with risk of developing both ER-positive and ER-negative tumors (9). The SNP is also associated with risk of *BRCA1* related breast cancers (15), which are primarily ER-negative or TN. *TOX3* encodes a protein containing an HMG-box that is speculated to be involved in the modification of DNA and chromatin structure (37).

Only a subset of the 22 susceptibility loci were associated with TN disease in this study. This suggests that there may be heterogeneity in the predisposition loci associated with different breast tumor subtypes. However, it is important to consider whether limited statistical power may have influenced our results. Among the 16 SNPs that did not reach

statistical significance in this study, the effect estimates for variants at 1p11.2, 2q35, 8q24, 9q31.2, 10p15.1, 10q21.2/*ZNF365*, 10q22.3/*ZMIZ1*, and *FGFR2* showed either no evidence for association or were in the opposite direction compared to the original GWAS findings. Interestingly, 2q35 has been associated with both ER-negative (19) and BRCA1-related breast cancer (21), and was marginally significant in a smaller set of TN breast cancer (19). However, we found no evidence for association at 2q35 among TN breast cancer, indicating that risk for this locus may be limited to non-TN, ER-negative breast cancer. In contrast, the ORs for SNPs at *CASP8*, 9p21.3, and *COX11* were comparable in magnitude to the original GWAS findings, while the ORs for variants at 3p24/*NEK10*, 5p12, *MAP3K1*, *LSP1*, and 11q13 had only mildly attenuated effects. Our results are also consistent with a recent study reporting associations between *MAP3K1*, 3p24/*NEK10*, *COX11*, and *CASP8* and ER-negative breast cancer (19). These results suggest that we may have had insufficient power to detect significant associations for these SNPs among TN breast cancers.

Several limitations should be considered when interpreting these results. First, different ascertainment criteria were used among the contributing breast cancer studies with cases being ascertained from population-based or hospital-based case-control studies. Importantly, genetic main effects models in other large breast cancer consortia such as BCAC have provided stable risk estimates for SNPs across a wide range of study designs. This would suggest that in the case of these genetic variants, ascertainment and study design issues had limited influence on the results of genetic association studies for breast cancer. The consistency in effect estimates among BRCA1-related breast cancers, ER negative breast cancer, and now triple negative breast cancer for variants at 19p13.1, 6q25, and *TOX3* provide additional evidence that these estimates are robust to variability in study design. Further, our evaluation of interactions with age was underpowered, and unavailability of family history on the majority of studies precluded investigations of interactions by family history. There is also variability in the criteria used to define ER, PR, and HER2 status of cases between studies (**Supplementary Table 2**). For HER2, cases with scores of 0 or 1 by IHC were defined as HER2 negative. Cases with IHC of 2+ were not included in order to minimize erroneous inclusion of HER2 positive cases. In general, cases were considered ER or PR negative based on IHC of tumors using thresholds of <1% of cells stained, <10% of cells stained, or an Allred score of 0-2, which incorporates both intensity and percentage of staining in tumor cells. In addition to variability in thresholds for positivity, factors such as tissue fixation, antibody choice, and interpretation of positive immunostaining may also affect the definition of ER or PR status across study sites (38, 39). The resulting heterogeneity in the definition of triple negative breast cancer may influence our ability to detect associations with susceptibility loci that are specific to triple negative or ER negative disease. However, we did successfully identify six genetic loci associated with triple negative disease, and the lack of heterogeneity in effect estimates across study sites in this analysis (Figure 1) would suggest that our findings are generally robust to the differences noted above. Additionally, in a sensitivity analysis including only cases from studies with the most stringent criteria for defining TN cases (<1% of cells stained positive for ER and PR, HER2 0 or 1+ on IHC), the effect estimates were very similar to those from the complete analysis for the six SNPs in *ESR1*, 19p13.11, *TOX3*, and *RAD51L1*, with some attenuation of significance. Finally, it is important to note that the results of this study are specific to Caucasian women. While greater proportions of African Americans and Latinas than Caucasians develop TN breast cancer, it is not known whether similar associations with the SNPs described here exist in these populations. Further studies are needed to address this question.

In conclusion, our study provides convincing evidence for genetic susceptibility to TN breast cancer and suggests that susceptibility loci may differ by histological breast tumor subtype, defined by ER, PR and HER2 status. These findings add to the evidence suggesting

that these subtypes likely arise through distinct etiologic pathways. Additional studies, such as those from the Breast Cancer Association Consortium, will be important for determining whether these SNPs are exclusively associated with ER-negative, TN disease, or even basal breast cancer, a more refined subgroup of TN tumors. Fine mapping and functional analyses of these susceptibility loci are needed to identify the casual variants and mechanisms underlying the associations with TN breast cancer risk.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

Mammary Carcinoma Risk Factor Investigation (MARIE)

MARIE would like to thank Tracy Slanger and Elke Mutschelknauss for their valuable contributions, and S. Behrens, R. Birr, W. Busch, U. Eilber, B. Kaspereit, N. Knese, K. Smit, for their excellent technical assistance.

Melbourne Collaborative Cohort Study (MCCS)

We acknowledge the contribution of the MCCS investigators John L Hopper, Dallas R English, and Melissa C Southey.

Sheffield Breast Cancer Study (SBCS)

We thank Helen Cramp, Dan Connley and Ian Brock for patient recruitment, database management and DNA preparation respectively.

Prospective Study of Outcomes in Sporadic Versus Hereditary Breast Cancer (POSH)

We thank the 126 participating investigators who recruited cases to the study and the NCRN for supporting recruitment to the study.

Leuven Multidisciplinary Breast Centre (LMBC)

LMBC thanks Gilian Peuteman, Dominiek Smeets and Sofie van Soest for Technical assistance.

Mayo Clinic Breast Cancer Study (MCBCS)

We would like to thank Georgia Chenevix-Trench for her valuable contributions.

Helsinki Breast Cancer Study (HEBCS)

HEBCS thanks RN Hanna Jäntti and Irja Erkkilä for their help with the patient data and samples and Drs. Päivi Heikkilä, Ari Ristimäki, Tuomas Heikkinen, Mira Heinonen and Laura Hautala for their help with the tumor marker and pathology information, and gratefully acknowledges the Finnish Cancer Registry for the cancer data. The population allele and genotype frequencies were obtained from the data source funded by the Nodic Center of Excellence in Disease Genetics based on samples regionally selected from Finland, Sweden and Denmark.

Breast Cancer in Galway Genetic Study (BIGGS)

Thanks are given to Drs Gabrielle Colleran, Niall McInerney, Nicola Miller and Professor Michael Kerin, University Hospital Galway, for their help collecting patient data and samples.

Amsterdam Breast Cancer Study (ABCS)

We acknowledge ABCS/BOSOM study collaborators, among others LJ Van't Veer, FE van Leeuwen, R van Hien, S Cornelissen, A Broeks and AJ van den Broek, and the NKI-AVL Family Cancer Clinic, especially FB Hogervorst.

Australian Breast Cancer Tissue Bank (ABCTB)

RLB is a Cancer Institute New South Wales Fellow.

Oulu Breast Cancer Study (OBCS)

We wish to thank Mervi Grip and Kari Mononen for their help with patient contacts and sample and data collection, and Meeri Otsukka for assistance with sample and data handling.

Kuopio Breast Cancer Project (KBCP)

KBCP is grateful to Mrs Eija Myöhänen and Mrs Helena Kemiläinen for their skillful assistance.

Grant Support

Mammary Carcinoma Risk Factor Investigation (MARIE)

The MARIE study was supported by the Deutsche Krebshilfe e.V., grant number 70-2892-BR I, the Hamburg Cancer Society, the German Cancer Research Center (DKFZ) and the DNA extraction and genotype work in part by the Federal Ministry of Education and Research (BMBF) Germany grant 01KH0402.

Gene Environment Interaction and Breast Cancer in Germany (GENICA)

The GENICA Network was funded by the Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0 and 01KW0114, the Robert Bosch Foundation of Medical Research, Stuttgart, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, and University Tübingen, Germany (HB, Christina JustenhovenJ); Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany (UH); Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany (YDK, Christian Baisch); Institute of Pathology, Medical Faculty of the University of Bonn, Germany (Hans-Peter Fischer); Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, Germany (Thomas Brüning, Beate Pesch, Volker Harth, Sylvia Rabstein)

Melbourne Collaborative Cohort Study (MCCS)

The MCCS was supported by Australian NHMRC grants 209057, 251553 and 504711 and infrastructure provided by the Cancer Council Victoria.

Sheffield Breast Cancer Study (SBCS)

The SBCS was supported by the Breast Cancer Campaign (grant 2004Nov49 to AC), and by Yorkshire Cancer Research core funding.

Dana Farber Cancer Institute (DFCI)

This work was supported in part by the DFCI Breast Cancer SPORE NIH P50 CA089393.

Prospective Study of Outcomes in Sporadic Versus Hereditary Breast Cancer (POSH)

The POSH study (CI DM Eccles) was funded by Cancer Research UK. Blood samples were collected by the University of Southampton Cancer Sciences Human Tissue Bank (HTA license 12009).

Molecular Diagnostics Laboratory IRRP, National Centre for Scientific Research (DEMOKRITOS)

This work was supported by the Hellenic Cooperative Oncology Group research grant (HR R\_BG/04) and the Greek General Secretary for Research and Technology (GSRT) Program, Research Excellence II, funded at 75% by the European Union.

Bavarian Breast Cancer Cases and Controls (BBCC)

Peter Fasching was partly funded by the Dr. Mildred Scheel Stiftung of the Deutsche Krebshilfe e.V.

British Breast Cancer Study (BBCS)

The BBC NCRN study is funded by Cancer Research UK and Breakthrough Breast Cancer and acknowledges NHS funding to the NIHR biomedical Research Centre and the National Cancer Research Network (NCRN).

#### Leuven Multidisciplinary Breast Centre (LMBC)

LMBC is supported by European Union Framework Programme 6 Project LSHC-CT-2003-503297 (the Cancerdegradome) and by the 'Stichting tegen Kanker' (232-2008).

#### Oulu Breast Cancer Study (OBCS)

OBCS was supported by grants and other funding from the Finnish Cancer Foundation, the Sigrid Juselius Foundation, the Academy of Finland, the University of Finland, and Oulu University Hospital.

#### Mayo Clinic Breast Cancer Study (MCBCS)

MCBCS was supported by NIH Grants CA122340 and a Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), and grants from the Komen Foundation for the Cure and the Breast Cancer Research Foundation (BCRF).

#### Study of Epidemiology and Risk factors in Cancer Heredity (SEARCH)

SEARCH was supported by Cancer Research UK grants C1287/A7497, C490/A11021, C1287/A10118 and C1287/A5260.

#### Helsinki Breast Cancer Study (HEBCS)

The HEBCS study has been financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (132473), the Finnish Cancer Society, and the Sigrid Juselius Foundation.

#### Fox Chase Cancer Center (FCCC)

A.K.G. was funded by SPORE P-50CA83638, U01CA69631, 5U01CA113916, and the Eileen Stein Jacoby Fund.

#### Roswell Park Cancer Institute (RPCI)

Data and samples were obtained from the RPCI DataBank and BioRepository (DBBR) (40), a Cancer Center Support Grant Shared Resource (P30 CA016056-32).

#### Städtisches Klinikum Karlsruhe and Deutsches Krebsforschungszentrum Breast Cancer Study (SKKDKFZS)

The SKKDKFZS study was supported by the Deutsches Krebsforschungszentrum.

#### Breast Cancer in Galway Genetic Study (BIGGS)

ES is funded by the National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre, Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust.

#### Australian Breast Cancer Tissue Bank (ABCTB)

The ABCTB is generously supported by the National Health and Medical Research Council of Australia, The Cancer Institute NSW and the National Breast Cancer Foundation.

#### Amsterdam Breast Cancer Study (ABCS)

MKS was funded by the Dutch Cancer Society grant number 2009-4363.

## References

1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. *N Engl J Med.* 2010; 363:1938–48. [PubMed: 21067385]
2. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. *Cancer Epidemiol Biomarkers Prev.* 2007; 16:439–43. [PubMed: 17372238]

3. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, et al. Triple-negative breast cancer: risk factors to potential targets. *Clin Cancer Res.* 2008; 14:8010–8. [PubMed: 19088017]
4. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, et al. Epidemiology of basal-like breast cancer. *Breast Cancer Res Treat.* 2008; 109:123–39. [PubMed: 17578664]
5. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. *Cancer.* 2007; 109:1721–8. [PubMed: 17387718]
6. Irvin WJ Jr, Carey LA. What is triple-negative breast cancer? *Eur J Cancer.* 2008; 44:2799–805. [PubMed: 19008097]
7. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature.* 2007; 447:1087–93. [PubMed: 17529967]
8. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, et al. A genome-wide association study identifies alleles in *FGFR2* associated with risk of sporadic postmenopausal breast cancer. *Nat Genet.* 2007; 39:870–4. [PubMed: 17529973]
9. Stacey SN, Manolescu A, Sulem P, Rafnar T, Gudmundsson J, Gudjonsson SA, et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. *Nat Genet.* 2007; 39:865–9. [PubMed: 17529974]
10. Stacey SN, Manolescu A, Sulem P, Thorlacius S, Gudjonsson SA, Jonsson GF, et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. *Nat Genet.* 2008; 40:703–6. [PubMed: 18438407]
11. Ahmed S, Thomas G, Ghoussaini M, Healey CS, Humphreys MK, Platte R, et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. *Nat Genet.* 2009; 41:585–90. [PubMed: 19330027]
12. Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, Cox DG, et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (*RAD51L1*). *Nat Genet.* 2009; 41:579–84. [PubMed: 19330030]
13. Zheng W, Long J, Gao YT, Li C, Zheng Y, Xiang YB, et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. *Nat Genet.* 2009; 41:324–8. [PubMed: 19219042]
14. Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, et al. Genome-wide association study identifies five new breast cancer susceptibility loci. *Nat Genet.* 2010; 42:504–7. [PubMed: 20453838]
15. Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, et al. A locus on 19p13 modifies risk of breast cancer in *BRCA1* mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nat Genet.* 2010; 42:885–92. [PubMed: 20852631]
16. Fletcher O, Johnson N, Orr N, Hosking FJ, Gibson LJ, Walker K, et al. Novel Breast Cancer Susceptibility Locus at 9q31.2: Results of a Genome-Wide Association Study. *J Natl Cancer Inst.* 2011
17. Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status. *Clin Cancer Res.* 2008; 14:8000–9. [PubMed: 19088016]
18. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. *PLoS Genet.* 2008; 4:e1000054. [PubMed: 18437204]
19. Broeks A, Schmidt MK, Sherman ME, Couch FJ, Hopper JL, Dite GS, et al. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. *Hum Mol Genet.* 2011
20. Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in *BRCA1* and *BRCA2* mutation carriers. *Am J Hum Genet.* 2008; 82:937–48. [PubMed: 18355772]


21. Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, et al. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. *Cancer Res.* 2010; 70:9742–54. [PubMed: 21118973]
22. Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, et al. A common coding variant in CASP8 is associated with breast cancer risk. *Nat Genet.* 2007; 39:352–8. [PubMed: 17293864]
23. Milne RL, Gaudet MM, Spurdle AB, Fasching PA, Couch FJ, Benitez J, et al. Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the Breast Cancer Association Consortium: a combined case-control study. *Breast Cancer Res.* 2010; 12:R110. [PubMed: 21194473]
24. Li J, Humphreys K, Darabi H, Rosin G, Hannelius U, Heikkinen T, et al. A genome-wide association scan on estrogen receptor-negative breast cancer. *Breast Cancer Res.* 2010; 12:R93. [PubMed: 21062454]
25. Leu M, Humphreys K, Surakka I, Rehnberg E, Muilu J, Rosenstrom P, et al. NordicDB: a Nordic pool and portal for genome-wide control data. *Eur J Hum Genet.* 2010; 18:1322–6. [PubMed: 20664631]
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials.* 1986; 7:177–88. [PubMed: 3802833]
27. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ.* 2003; 327:557–60. [PubMed: 12958120]
28. Stacey SN, Sulem P, Zanon C, Gudjonsson SA, Thorleifsson G, Helgason A, et al. Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus. *PLoS Genet.* 2010; 6:e1001029. [PubMed: 20661439]
29. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, et al. Control of mammary stem cell function by steroid hormone signalling. *Nature.* 2010; 465:798–802. [PubMed: 20383121]
30. Joshi PA, Jackson HW, Birstain AG, Di Grappa MA, Mote PA, Clarke CL, et al. Progesterone induces adult mammary stem cell expansion. *Nature.* 2010; 465:803–7. [PubMed: 20445538]
31. Tapper W, Hammond V, Gerty S, Ennis S, Simmonds P, Collins A, et al. The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer. *Breast Cancer Res.* 2008; 10:R108. [PubMed: 19094228]
32. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. *Nat Genet.* 2010; 42:880–4. [PubMed: 20852633]
33. Feng L, Huang J, Chen J. MERIT40 facilitates BRCA1 localization and DNA damage repair. *Genes Dev.* 2009; 23:719–28. [PubMed: 19261748]
34. Shao G, Patterson-Fortin J, Messick TE, Feng D, Shanbhag N, Wang Y, et al. MERIT40 controls BRCA1-Rap80 complex integrity and recruitment to DNA double-strand breaks. *Genes Dev.* 2009; 23:740–54. [PubMed: 19261746]
35. Wang B, Hurov K, Hofmann K, Elledge SJ. NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control. *Genes Dev.* 2009; 23:729–39. [PubMed: 19261749]
36. Lio YC, Mazin AV, Kowalczykowski SC, Chen DJ. Complex formation by the human Rad51B and Rad51C DNA repair proteins and their activities in vitro. *J Biol Chem.* 2003; 278:2469–78. [PubMed: 12427746]
37. O'Flaherty E, Kaye J. TOX defines a conserved subfamily of HMG-box proteins. *BMC Genomics.* 2003; 4:13. [PubMed: 12697058]
38. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. *Mod Pathol.* 2008; 21(Suppl 2):S8–S15. [PubMed: 18437174]
39. Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, et al. NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. *J Natl Compr Canc Netw.* 2009; 7(Suppl 6):S1–S21. quiz S2-3. [PubMed: 19755043]

40. Ambrosone CB, Nesline MK, Davis W. Establishing a cancer center data bank and biorepository for multidisciplinary research. *Cancer Epidemiol Biomarkers Prev.* 2006; 15:1575–7. [PubMed: 16985014]

a) rs2046210 (6q25.1, *ESR1*)

Country	OR (95% CI)	Cases	Controls
American	1.21 (1.03-1.44)	711	448
Australian	1.38 (0.90-2.11)	186	59
British	1.58 (1.15-2.16)	573	111
Finnish	1.19 (0.71-1.99)	101	88
German	1.31 (1.11-1.55)	807	501
Greek	1.35 (0.94-1.95)	273	85
Irish	1.15 (0.62-2.13)	29	67
Swedish	0.89 (0.45-1.79)	27	26
<b>All</b>	<b>1.29 (1.17-1.42)</b>	<b>2707</b>	<b>1385</b>


*P* heterogeneity = 0.827



b) rs12662670 (6q25.1, *ESR1*)

Country	OR (95% CI)	Cases	Controls
American	1.44 (1.05-1.96)	711	448
Australian	1.49 (0.7-3.16)	186	59
British	1.24 (0.98-1.57)	573	1485
Finnish	1.36 (0.46-3.99)	101	88
German	1.42 (1.07-1.88)	807	501
Greek	1.57 (0.88-2.8)	273	85
Irish	0.78 (0.22-2.81)	29	67
Swedish	0.39 (0.11-1.37)	27	26
<b>All</b>	<b>1.33 (1.15-1.53)</b>	<b>2707</b>	<b>2759</b>


*P* heterogeneity = 0.590



c) rs8170 (19p13.11, *C19orf62:ANKLE1:ABHD8*)

Country	OR (95% CI)	Cases	Controls
American	1.23 (1.05-1.43)	746	1574
Australian	1.02 (0.77-1.36)	206	716
British	1.34 (1.13-1.58)	579	1485
Finnish	1.12 (0.83-1.51)	186	309
German	1.36 (1.15-1.62)	933	716
Greek	1.37 (0.85-2.22)	273	85
Irish	2.14 (1.00-4.55)	29	67
Swedish	1.13 (0.35-3.57)	27	26
<b>All</b>	<b>1.27 (1.17-1.38)</b>	<b>2979</b>	<b>4978</b>


*P* heterogeneity = 0.531



d) rs8100241 (19p13.11, *C19orf62:ANKLE1:ABHD8*)

Country	OR (95% CI)	Cases	Controls
American	0.87 (0.77-0.99)	746	1573
Australian	0.80 (0.52-1.23)	207	59
British	0.80 (0.70-0.92)	579	1485
Finnish	0.75 (0.58-0.96)	186	309
German	0.87 (0.76-1.00)	933	716
Greek	0.77 (0.53-1.12)	273	85
Irish	1.00 (0.52-1.93)	29	67
Swedish	0.75 (0.32-1.78)	27	26
<b>All</b>	<b>0.84 (0.78-0.90)</b>	<b>2980</b>	<b>4320</b>


*P* heterogeneity = 0.937



e) rs3803662 (16q12.1, *TOX3*)

Country	OR (95% CI)	Cases	Controls
American	1.16 (1.02-1.33)	746	1574
Australian	1.29 (1.02-1.65)	207	715
British	1.08 (0.93-1.26)	579	1481
Finnish	1.05 (0.80-1.37)	186	309
German	1.29 (1.10-1.52)	933	716
Greek	1.13 (0.78-1.63)	273	85
Irish	0.70 (0.32-1.53)	29	67
Swedish	1.70 (0.70-4.12)	27	26
<b>All</b>	<b>1.17 (1.09-1.26)</b>	<b>2980</b>	<b>4973</b>


*P* heterogeneity = 0.511



f) rs999737 (14q24.1, *RAD51L1*)

Country	OR (95% CI)	Cases	Controls
American	0.84 (0.73-0.98)	745	1574
Australian	0.70 (0.53-0.92)	206	715
British	0.89 (0.76-1.05)	579	1485
Finnish	0.93 (0.67-1.29)	186	309
German	0.94 (0.81-1.10)	933	716
Greek	0.78 (0.52-1.17)	273	85
Irish	0.73 (0.36-1.51)	29	67
Swedish	0.56 (0.22-1.41)	27	26
<b>All</b>	<b>0.86 (0.80-0.93)</b>	<b>2978</b>	<b>4977</b>

*P* heterogeneity = 0.622



**Figure 1. Breast cancer susceptibility loci and risk of TN breast cancer**

Forest plots for six breast cancer susceptibility loci and risk of TN breast cancer are shown by country. Country-specific odds ratios (95% CIs) are denoted by black boxes (black lines). Overall OR estimates are represented by black diamonds, where diamond width corresponds to 95% CI bounds. Box and diamond heights are inversely proportional to precision of the OR estimate.  $I^2$  values were 0 for each of these 6 SNPs, indicating no heterogeneity by country.

**Table 1**

Subjects by country and genotyping platform (iPLEX, GWAS)

Country	No. of studies	Age range (mean) <sup>a</sup>		Years of diagnosis <sup>a</sup>	iPLEX			GWAS			Combined		
		Cases	Controls		Cases	Controls	Total	Cases	Controls	Total	Cases	Controls	Total
U.S.A	5	25 - 92 (52)	24 - 92 (62)	1990 - 2010	711	448	1159	35	1126	1161	746	1574	2320
Australia	3	25 - 91 (56)	29 - 72 (46)	1990 - 2009	186	59	245	21	657	678	207	716	923
U.K.	5	22 - 93 (45)	42 - 81 (53)	1971 - 2010	573	111	684	6	1374	1380	579	1485	2064
Finland	3	27 - 90 (55)	18 - 80 (57)	1990 - 2004	101	88	189	85	221	306	186	309	495
Germany	6	22 - 88 (57)	24 - 81 (58)	1993 - 2008	740	501	1241	126	215	341	866	716	1582
Greece	1	21 - 79 (53)	34 - 82 (50)	1997 - 2010	273	85	358	0	0	0	273	85	358
Netherlands	1	26 - 62 (39)	NA	1995 - 2007	67	0	67	0	0	0	67	0	67
Sweden	1	48 - 88 (62)	48 - 85 (62)	1998 - 2000	27	26	53	0	0	0	27	26	53
<b>Total</b>	<b>25</b>	<b>21 - 93 (52)</b>	<b>18 - 92 (56)</b>	<b>1971 - 2010</b>	<b>2707</b>	<b>1385</b>	<b>4092</b>	<b>273</b>	<b>3593</b>	<b>3866</b>	<b>2980</b>	<b>4978</b>	<b>7958</b>

<sup>a</sup>Study-specific distributions shown in Supplementary Table 1

**Table 2**

Breast cancer susceptibility SNP (n=22) associations with TN breast cancer in a log-additive model

SNP	Gene/Locus	Chr	Tested (Minor) Allele	Overall				iPLEX				Published OR (95% CI)
				Cases	Controls	P-trend	OR (95% CI)	Cases	Controls	P-trend	OR (95% CI)	
rs11249433	<i>1p11.2</i>	1p11.2	G	2976	4968	0.27	0.96 (0.90-1.03)	2707	1385	0.54	0.97 (0.88-1.07)	1.16 (1.09-1.24) (12)
rs17468277 <sup>a</sup>	<i>CASP8</i>	2q33.1	T	2979	4977	0.005	0.87 (0.78-0.96)	2707	1385	0.16	0.90 (0.78-1.04)	0.88 (0.84-0.92) (22)
rs13387042	<i>2q35</i>	2q35	G	2977	4976	0.26	0.96 (0.90-1.03)	2705	1384	0.92	0.99 (0.91-1.09)	1.20 (1.14-1.26) (9)
rs4973768	<i>SLC4A7:NEK10</i>	3p24	T	2960	4974	0.24	1.04 (0.97-1.12)	2688	1382	0.21	1.06 (0.97-1.17)	1.11 (1.08-1.13) (11)
rs10941679	<i>MRPS30:FGF10</i>	5p12	G	2705	1385	0.43	1.04 (0.94-1.16)	2705	1385	0.43 <sup>b</sup>	1.04 (0.94-1.16)	1.19 (1.11-1.28) (10)
rs889312	<i>MAP3K1</i>	5q11.2	C	2844	2757	0.13	1.07 (0.98-1.17)	2707	1385	0.20	1.07 (0.97-1.19)	1.12 (1.08-1.16) (7)
rs2046210	<i>ESR1</i>	6q25.1	A	2707	1385	4.38 × 10 <sup>-7</sup>	1.29 (1.17-1.42)	2707	1385	4.38 × 10 <sup>-7b</sup>	1.29 (1.17-1.42)	1.15 <sup>c</sup> (1.03-1.28) (13)
rs12662670	<i>ESR1</i>	6q25.1	G	2707	2759	1.13 × 10 <sup>-4</sup>	1.33 (1.15-1.53)	2707	1385	3.52 × 10 <sup>-4</sup>	1.37 (1.15-1.62)	1.18 (1.10-1.26) (28)
rs13281615	<i>8q24</i>	8q24.21	G	2841	3413	0.79	0.99 (0.92-1.07)	2707	1385	0.70	0.98 (0.89-1.08)	1.08 (1.05-1.12) (7)
rs1011970 <sup>a</sup>	<i>CDKN2BAS:CDKN2A:CDKN2B</i>	9p21.3	T	2979	4977	0.13	1.07 (0.98-1.17)	2707	1385	0.02	1.16 (1.02-1.31)	1.09 (1.04-1.14) (14)
rs865686	<i>LOC100128657</i>	9q31.2	G	2979	4971	0.65	1.02 (0.95-1.09)	2707	1385	0.96	1.00 (0.91-1.1)	0.89 (0.85-0.92) (16)
rs2380205	<i>ANKRD16:FBXO18</i>	10p15.1	T	2979	4974	0.71	0.99 (0.92-1.06)	2707	1385	0.94	1.00 (0.91-1.1)	0.94 (0.91-0.89) (14)
rs10509168	<i>ZNF365</i>	10q21.2	T	2980	4976	0.79	1.01 (0.94-1.08)	2707	1385	0.88	0.99 (0.90-1.09)	0.86 (0.82-0.91) (14)
rs704010	<i>ZMIZ1</i>	10q22.3	T	2964	4963	0.80	0.99 (0.93-1.06)	2692	1370	0.99	1.00 (0.91-1.1)	1.07 (1.03-1.11) (14)
rs2981582	<i>FGFR2</i>	10q26	A	2707	2756	0.24	0.95 (0.88-1.03)	2707	1385	0.64	0.98 (0.89-1.08)	1.26 (1.22-1.29) (7)
rs3817198	<i>LSP1</i>	11p15.5	C	2929	4756	0.49	1.03 (0.95-1.10)	2707	1385	0.68	1.02 (0.92-1.13)	1.07 (1.04-1.11) (7)
rs614367	<i>MYEOV:CCND1</i>	11q13	T	2926	4749	0.17	1.07 (0.97-1.18)	2707	1385	0.12	1.12 (0.97-1.28)	1.15 (1.10-1.20) (14)
rs999737	<i>RAD51L1</i>	14q24.1	T	2978	4977	2.96 × 10 <sup>-4</sup>	0.86 (0.80-0.93)	2706	1385	0.05	0.90 (0.80-1.00)	0.94 (0.88-0.99) (12)
rs3803662	<i>TOX3</i>	16q12.1	A	2980	4973	3.66 × 10 <sup>-5</sup>	1.17 (1.09-1.26)	2707	1385	8.25 × 10 <sup>-4</sup>	1.20 (1.08-1.33)	1.19 (1.15-1.23) (7)
rs6504950	<i>COX11</i>	17q23.2	A	2707	1385	0.54	0.97 (0.87-1.07)	2707	1385	0.54 <sup>b</sup>	0.97 (0.87-1.07)	0.95 (0.92-0.97) (11)
rs8170	<i>C19orf62:ANKLE1</i>	19p13.1	T	2979	4978	2.25 × 10 <sup>-8</sup>	1.27 (1.17-1.38)	2707	1385	7.30 × 10 <sup>-8</sup>	1.40 (1.24-1.58)	1.26 (1.17-1.35) (21)
rs8100241	<i>C19orf62:ANKLE1</i>	19p13.1	A	2980	4320	8.66 × 10 <sup>-7</sup>	0.84 (0.78-0.90)	2707	1385	1.81 × 10 <sup>-6</sup>	0.79 (0.71-0.87)	0.84 (0.80-0.89) (21)

<sup>a</sup>These SNPs showed evidence of country-based heterogeneity.

<sup>b</sup>No additional samples included in overall analysis compared to iPLEX-only

<sup>c</sup>Estimated OR in Europeans